Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5460025 · 1 trial · 2 indications
ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by investigator assessment.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose escalation of GSK5460025 monotherapy | EXPERIMENTAL | Participants will receive GSK5460025 as monotherapy. |
| Part 2: Dose expansion of GSK5460025 monotherapy | EXPERIMENTAL | Participants will receive GSK5460025 as monotherapy. |
| Name | Type | Description |
|---|---|---|
| GSK5460025 | DRUG | GSK5460025 will be administered |
Inclusion Criteria: * Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor * Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) stat...
GSK5460025 is an investigational small molecule being studied for the treatment of solid tumors, including colorectal neoplasms. It is currently in Phase 1 clinical development for oncology indications. The drug is being evaluated alone and in combination with other anti-cancer agents in patients with solid tumors.
GSK5460025 is being developed by GSK plc, a global biopharmaceutical company. GSK plc is listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to investigate the safety and preliminary efficacy of this investigational oncology drug.
GSK5460025 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the safety and preliminary efficacy of GSK5460025 in patients with solid tumors.
GSK5460025 is being studied in a Phase 1 clinical trial registered as NCT07213609. This trial is investigating the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in participants with solid tumors. The trial is currently recruiting and aims to enroll 47 participants.
The specific molecular target of GSK5460025 has not been disclosed in publicly available information. The drug is being studied for its potential anti-cancer activity in solid tumors, including colorectal neoplasms. Further details about its mechanism of action are not yet available from the clinical trial data.